StockData
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. (NAMS) stock

NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.39−0.07 (-0.36%)

Close on Nov 17, 2026Market cap $2.32BP/E –Yield –

Earnings

NewAmsterdam Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$3.70M
-80.6% on a year earlier
EPS, Q2 FY2026
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of NewAmsterdam Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$3.70M-80.6%–Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$3.00M0.0%–Release
Q4 FY2025ended Dec 31, 2025Feb 18, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$300.00K-99.0%–Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$19.10M+730.4%–Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$3.00M+114.3%–Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024before the open$29.10M–-$0.18Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$2.30M–-$0.41Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$1.40M–-$1.06Release
Q4 FY2023ended Dec 31, 2023Feb 28, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

NewAmsterdam Pharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When NewAmsterdam Pharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases NewAmsterdam Pharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Results
  3. News
  4. Results
  5. Update
  6. Results
  7. Results
  8. Results
  9. Results
  10. Update
  11. Update
  12. Results
  13. Update
  14. Update
  15. Update

See a number that looks wrong?